Santalum album ointment - Santalis Healthcare

Drug Profile

Santalum album ointment - Santalis Healthcare

Alternative Names: Albuterpenoid -Santalis Healthcare ViroXis; East Indian sandalwood oil - Santalis Healthcare; EISO - Santalis Healthcare

Latest Information Update: 29 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroXis
  • Developer Santalis Healthcare Corporation; ViroXis
  • Class Anti-infectives; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Warts
  • Discontinued Acne; Mycoses; Skin and soft tissue infections; Skin cancer; Wounds

Most Recent Events

  • 25 Jan 2016 ViroXis is now called Santalis Healthcare
  • 11 Jan 2016 Santalis Pharmaceuticals plans a phase III trial for Warts (In children) in USA
  • 15 Jun 2015 Santalum album ointment is still in phase II trials for Warts in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top